Shamburg News · 8-K filed Oct 23, 2026, 10:31 AM EDT
Bolt Biotherapeutics Completes Acquisition of Prana Therapies and Announces $120 Million Private Placement
BOLT · Bolt Biotherapeutics, Inc.
- Acquisition
- Financing
- Material agreement
- Leadership change
- Other event
- Reg FD disclosure
- Materiality: high
On October 23, 2026, Bolt Biotherapeutics completed its merger with Prana Therapies under a Merger Agreement, issuing 430,746 common shares and 16,360.929 Series D preferred shares to Prana stockholders. Concurrently, the company entered a Securities Purchase Agreement for a private placement of 13,995.311 Series D preferred shares with warrants for $120 million in upfront gross proceeds, with closing expected October 26, 2026. Sheila Gujrathi was appointed to the Board as a Class II director and as Chief Strategy Officer effective after the First Effective Time.
Source: SEC EDGAR, Form 8-K, Items 1.01, 1.02, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01, accession 0001193125-26-429647.
Written from the filing by Shamburg Markets. Figures are as reported by the company.